4/22
05:33 pm
blte
Dry Age-related Macular Degeneration Seven Major Market to Exhibit Growth at a CAGR of 19.8% by 2034 | DelveInsight [Yahoo! Finance]
Medium
Report
Dry Age-related Macular Degeneration Seven Major Market to Exhibit Growth at a CAGR of 19.8% by 2034 | DelveInsight [Yahoo! Finance]
4/22
05:31 pm
blte
Dry Age-related Macular Degeneration Seven Major Market to Exhibit Growth at a CAGR of 19.8% by 2034 | DelveInsight
Medium
Report
Dry Age-related Macular Degeneration Seven Major Market to Exhibit Growth at a CAGR of 19.8% by 2034 | DelveInsight
4/22
05:31 pm
blte
Dry Age-related Macular Degeneration Seven Major Market to Exhibit Growth at a CAGR of 19.8% by 2034 | DelveInsight
Medium
Report
Dry Age-related Macular Degeneration Seven Major Market to Exhibit Growth at a CAGR of 19.8% by 2034 | DelveInsight
4/10
11:19 am
blte
Does Belite Bio (BLTE) Have the Potential to Rally 41.14% as Wall Street Analysts Expect? [Yahoo! Finance]
Low
Report
Does Belite Bio (BLTE) Have the Potential to Rally 41.14% as Wall Street Analysts Expect? [Yahoo! Finance]
3/22
11:19 am
blte
Belite Bio, Inc (NASDAQ: BLTE) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $59.00 price target on the stock.
Medium
Report
Belite Bio, Inc (NASDAQ: BLTE) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $59.00 price target on the stock.
3/22
08:18 am
blte
Belite Bio Announces PMDA Submission of Tinlarebant for Stargardt Disease Clinical Trial in Japan [Yahoo! Finance]
Low
Report
Belite Bio Announces PMDA Submission of Tinlarebant for Stargardt Disease Clinical Trial in Japan [Yahoo! Finance]
3/22
08:00 am
blte
Belite Bio Announces PMDA Submission of Tinlarebant for Stargardt Disease Clinical Trial in Japan
Low
Report
Belite Bio Announces PMDA Submission of Tinlarebant for Stargardt Disease Clinical Trial in Japan
3/20
07:45 am
blte
Here's Why We're Not Too Worried About Belite Bio's (NASDAQ:BLTE) Cash Burn Situation [Yahoo! Finance]
Low
Report
Here's Why We're Not Too Worried About Belite Bio's (NASDAQ:BLTE) Cash Burn Situation [Yahoo! Finance]
3/18
03:16 pm
blte
Belite Bio, Inc (NASDAQ: BLTE) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $59.00 price target on the stock.
Low
Report
Belite Bio, Inc (NASDAQ: BLTE) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $59.00 price target on the stock.
3/11
10:31 pm
blte
Belite Bio Announces Availability of Annual Report on Form 20-F Through Company Website [Yahoo! Finance]
High
Report
Belite Bio Announces Availability of Annual Report on Form 20-F Through Company Website [Yahoo! Finance]
3/11
10:28 pm
blte
Belite Bio Announces Availability of Annual Report on Form 20-F Through Company Website
High
Report
Belite Bio Announces Availability of Annual Report on Form 20-F Through Company Website
3/11
09:44 pm
blte
Belite Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update [Yahoo! Finance]
High
Report
Belite Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update [Yahoo! Finance]
3/11
09:27 pm
blte
Belite Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
High
Report
Belite Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
3/6
08:00 am
blte
Belite Bio to Host Webcast on March 12, 2024, to Discuss Fourth Quarter and Full Year 2024 Financial Results
Low
Report
Belite Bio to Host Webcast on March 12, 2024, to Discuss Fourth Quarter and Full Year 2024 Financial Results
3/4
08:00 am
blte
Belite Bio to Participate in the Leerink Partners Global Biopharma Conference
Low
Report
Belite Bio to Participate in the Leerink Partners Global Biopharma Conference
3/1
08:58 am
blte
Dry Age-related Macular Degeneration (Dry-AMD) Drug Pipeline Insight Landscape Report 2024: Comprehensive Insights About 70+ Companies and 80+ Pipeline Drugs [Yahoo! Finance]
Low
Report
Dry Age-related Macular Degeneration (Dry-AMD) Drug Pipeline Insight Landscape Report 2024: Comprehensive Insights About 70+ Companies and 80+ Pipeline Drugs [Yahoo! Finance]
2/14
07:00 pm
blte
Global Dry Age Related Macular Degeneration Market Report 2024-2030: Competition Intensifies as Companies Focus on Product Quality in Dry AMD Market
Low
Report
Global Dry Age Related Macular Degeneration Market Report 2024-2030: Competition Intensifies as Companies Focus on Product Quality in Dry AMD Market
2/7
08:10 am
blte
Belite Bio to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference [Yahoo! Finance]
Low
Report
Belite Bio to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference [Yahoo! Finance]
2/7
08:00 am
blte
Belite Bio to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
Low
Report
Belite Bio to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference